Albumin-bound paclitaxel combined with loplatin versus docetaxel combined with loplatin in the perioperative treatment of advanced gastric cancer

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000029714

Enrollment

Unknown

Registered

2020-02-09

Start date

2020-02-01

Completion date

Unknown

Last updated

2020-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

experimental group:Albumin-bound paclitaxel, Loplatin and Tegafur

historical control group:Docetaxel, Loplatin and Tegafur

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. The pathological diagnosis was gastric adenocarcinoma; 2. Non-bed case aged 18-75 years; 3. The ECOG score is less than or equal to 1; 4. No antitumor therapy(such as surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy); 5. It is expected to be able to endure abdominal surgery above grade 3; 6. Subjects' baseline blood routine and biochemical indicators met the following criteria: WBC > 4.0 * 10^9/L; ANC > 1.5*10^9/L; Hb >= 80 g/L; PLT >= 100*10^9/L; Serum bilirubin = 6 months.

Exclusion criteria

Exclusion criteria: 1. Patients with other malignant tumors, except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix; 2. Her-2 test positive Patients who are willing to receive herceptin therapy; 3. Pregnant or lactating women who are in the reproductive period and do not take effective contraceptive measures, or who have fertility requirements during the study period; 4. Severe, uncontrolled medical conditions and infections; Chronic bowel disease or short bowel syndrome; 5. Major organ failure, such as compensatory cardiopulmonary, liver and kidney failure;Severe liver and kidney dysfunction, affecting normal drug metabolism; 6. Patients with other surgical contraindications, such as uncontrollable serious diseases (including atrial fibrillation, angina, cardiac dysfunction, etc.); 7. The investigators concluded that patients with a clear tendency to gastrointestinal bleeding and/or abnormal coagulation function (INR > 1.5) had a tendency to bleeding; 8. Active HBV or HCV; 9. Peripheral neurosisNCT-CTCAE >= level 2; 10. Patients with drug allergy to the study protocol;The investigators determined that the patients were not suitable for this study.

Design outcomes

Primary

Measure	Time frame
R0 resection rate;Objective response rate;security;	—

Secondary

Measure	Time frame
Overall survival;	—

Countries

China

Contacts

Public ContactYang Jianjun

Xijing Hospital of Air Force Military Medical University

15029803518@163.com+86 13572533693

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026